Efficacy comparison of fruquintinib, regorafenib monotherapy or plus programmed death-1 inhibitors for microsatellite stable metastatic colorectal cancer

Table 3 efficacy comparisons in patients treated with regorafenib, regorafenib plus programmed death-1 inhibitors, fruquintinib, and fruquintinib plus programmed death-1 inhibitors regimens

Efficacy	F	R	FP	RP	P(F vs FP)	P(R vs RP)	P(F vs R)	P(FP vs RP)
ORR	4.3%	6.0%	11.6%	4.9%	0.097	> 0.999	0.714	0.116
DCR	60.0%	61.2%	74.7%	70.4%	0.044a	0.240	0.886	0.517
6-month PFS, month	27.8%	27.8%	47.1%	22.0%	0.014a	0.521	0.862	0.001a
1-yr OS	61.3%	60.4%	62.2%	53.9%	0.922	0.259	0.945	0.157
3-yr OS	26.6%	29.7%	10.0%	12.9%	0.849	0.066	0.754	0.120
PFS, month	3.5	3.6	4.9	3.0	0.057	0.534	0.747	0.030a
OS, month	14.6	15.7	16.7	14.1	0.849	0.080	0.754	0.120

^aP < 0.05, and the difference is statistically significant.

F: Fruquintinib; R: Regorafenib; FP: Fruquintinib plus programmed death-1 inhibitors; RP: Regorafenib plus programmed death-1 inhibitors; ORR: Objective response rate; DCR: Disease control rate; PFS: Progression-free survival; OS: Overall survival.